Efficacy of an Electrophile Scavenger in the Prevention of Gastrointestinal Inflammatory Carcinogenesis

亲电子清除剂在预防胃肠道炎症癌发生中的功效

基本信息

  • 批准号:
    10257862
  • 负责人:
  • 金额:
    $ 40万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-04-09 至 2023-09-30
  • 项目状态:
    已结题

项目摘要

SUMMARY: Many cancers are recognized to have an inflammatory etiology. Gastric cancer, the third leading cause of cancer deaths worldwide, is the prototype- it is caused by infection with the bacterial pathogen Helicobacter pylori in 90% of cases. For colorectal cancer (CRC), the second leading cause of cancer deaths, inflammatory bowel disease (IBD) is a frequent precursor lesion. This STTR Phase I proposal is a partnership between the Wilson Lab at Vanderbilt University Medical Center (VUMC), which is focused on gastrointestinal inflammation- associated carcinogenesis, and MTI BioTech, Inc. (MTI), who are together developing a new therapeutic strategy to prevent cancer. Under conditions of chronic mucosal inflammation, increased enzyme activities result in formation of dicarbonyl electrophiles, products of lipid peroxidation that include isolevuglandins (isoLGs), malondialdehyde, 4-oxo-nonenal, and acrolein, all of which can form adducts with DNA, histones, and proteins. This adduct formation may lead to somatic genomic abnormalities and risk for neoplastic transformation. The compound 2-hydroxybenzylamine (2-HOBA) can serve as a scavenger of all electrophiles, thus preventing adduct formation. 2-HOBA is a natural product derived from buckwheat seeds. It has been shown to be highly bioavailable, with no toxicity, in rodents and in recent human Phase I clinical trials. 2-HOBA protects mice from oxidative damage in models of hypertension and Alzheimer’s disease. The Wilson Lab has discovered that isoLG adducts are increased i) in gastric tissues of patients and mice infected with H. pylori; ii) in the colon of humans with chronic colitis from inflammatory bowel disease, and colitis-associated cancer (CAC), and mice treated with azoxymethane-dextran sulfate sodium (AOM-DSS), a model of CAC. The Lab has found that a 2-HOBA analog, EtHOBA, which also scavenges electrophiles, markedly reduces gastric dysplasia and carcinoma in two models of H. pylori-induced gastric carcinoma, transgenic FVB/N insulin-gastrin (INS-GAS) mice and Mongolian gerbils, and reduces colonic tumorigenesis in the AOM-DSS CAC model. However, unlike 2-HOBA, EtHOBA has not reached development for human use. We hypothesize that electrophiles have a key role in inflammation-driven gastrointestinal carcinogenesis via formation of adducts to macromolecules and are new molecular targets for cancer prevention by 2-HOBA. We will determine the protective effect of 2-HOBA on H. pylori-induced gastric carcinogenesis in INS-GAS mice and gerbils (Aim 1) and on colitis-associated carcinogenesis in the AOM-DSS mouse model (Aim 2). Primary endpoints will be reduction in dysplasia, carcinoma, and tumor formation, and secondary endpoints will be effects on DNA damage and isoLG adducts. A successful STTR Phase I outcome will be a protective effect of 2-HOBA on gastric and colon carcinogenesis and will be the primary go/no go endpoint to a Phase II STTR project. We envision future studies testing 2-HOBA in animals in which disease is already fully established; further assessment of molecular mechanisms underlying protective effects, including in human organoids; and human clinical trials in patients with precancerous gastric and colon lesions.
摘要: 许多癌症都被认为是由炎症引起的。胃癌,第三大致癌原因 全球范围内的死亡,是原型-它是由感染幽门螺杆菌引起的 90%的病例。对于结直肠癌(CRC),癌症死亡的第二大原因是炎症性肠病 疾病(IBD)是常见的前驱病变。这项STTR第一阶段提案是威尔逊夫妇 范德比尔特大学医学中心(VUMC)的实验室,专注于胃肠道炎症- 和MTI生物技术公司(MTI Biotech,Inc.)共同开发一种新的治疗策略 来预防癌症。在慢性粘膜炎症的情况下,酶活性增加会导致 形成二羰基亲电体,这是脂质过氧化的产物,包括异uglandins(IsLGs), 丙二醛、4-氧代-壬烯醛和丙烯醛,所有这些都能与DNA、组蛋白和蛋白质形成加合物。 这种加合物的形成可能导致体细胞基因组的异常和肿瘤转化的风险。这个 化合物2-羟基苯甲胺(2-HOBA)可作为所有亲电体的清除剂,从而防止 加合物形成。2-HOBA是从荞麦种子中提取的天然产物。它已经被证明是高度的 在啮齿动物和最近的人类I期临床试验中,生物利用度为零,没有毒性。2-HOBA保护小鼠免受 高血压和阿尔茨海默病模型中的氧化损伤。威尔逊实验室发现,isoLG 幽门螺杆菌感染患者和小鼠的胃组织中的加合物增加;ii)人的结肠中 炎症性肠病引起的慢性结肠炎和结肠炎相关癌症(CAC),以及接受 偶氮甲烷-葡聚糖硫酸钠(AOM-DSS),CAC模型。实验室发现一种2-Hoba类似物, 在两种模型中,也清除亲电体的EtHOBA显著减少了胃不典型增生和肿瘤 幽门螺杆菌诱发的胃癌、转基因FVB/N胰岛素-胃泌素(INS-GAS)小鼠和蒙古沙土鼠, 并在AOM-DSS CAC模型中减少结肠肿瘤的发生。然而,与2-Hoba不同,EtHOBA没有 达到了供人类使用的开发。我们假设亲电体在炎症驱动中起着关键作用。 通过与大分子形成加合物而致癌,是治疗胃肠道肿瘤的新分子靶点 2-HOBA预防癌症。我们将确定2-HOBA对幽门螺杆菌诱导的胃的保护作用 INS-GAS小鼠和沙土鼠的致癌作用(目标1)和AOM-DSS的结肠炎相关致癌作用 小鼠模型(目的2)。主要终点是异型增生、癌症和肿瘤形成的减少,以及 次要终点将对DNA损伤和等LG加合物产生影响。一项成功的STTRI期成果 将是2-HOBA对胃癌和结肠癌发生的保护作用,并将是主要的GO/NO GO 第二阶段STTR项目的终点。我们设想未来的研究将在动物身上测试2-HOBA, 已经完全确定;进一步评估潜在的保护作用的分子机制,包括 在人类器官中;以及在胃癌和结肠癌前病变患者中进行的人类临床试验。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

John A Rathmacher其他文献

Post-prandial amino acid and leucine responses to serum albumin concentrate compared to whey protein concentrate in healthy subjects
Effects of 12 weeks of beta-hydroxy-beta-methylbutyrate free acid, adenosine triphosphate, or a combination on muscle mass, strength, and power in resistance trained individuals
  • DOI:
    10.1186/1550-2783-10-s1-p17
  • 发表时间:
    2013-12-06
  • 期刊:
  • 影响因子:
    3.900
  • 作者:
    Ryan P Lowery;Jordan Joy;John A Rathmacher;Shawn M Baier;John C Fuller;Ralf Jäger;Stephanie M C Wilson;Jacob M Wilson
  • 通讯作者:
    Jacob M Wilson
Oral ATP administration improves blood flow response to exercise in an animal model and in resistance trained athletes
  • DOI:
    10.1186/1550-2783-10-s1-p16
  • 发表时间:
    2013-12-06
  • 期刊:
  • 影响因子:
    3.900
  • 作者:
    Ryan P Lowery;Michael D Roberts;Frank W Booth;Jordan Joy;Clayton L Cruthirds;John A Rathmacher;Shawn M Baier;John C Fuller;Christopher M Lockwood;Ralf Jäger;Joshua E Dudeck;Jacob M Wilson
  • 通讯作者:
    Jacob M Wilson

John A Rathmacher的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('John A Rathmacher', 18)}}的其他基金

2-HOBA for Treatment of Pulmonary Hypertension
2-HOBA 治疗肺动脉高压
  • 批准号:
    10698621
  • 财政年份:
    2021
  • 资助金额:
    $ 40万
  • 项目类别:
2-HOBA for Treatment of Pulmonary Hypertension
2-HOBA 治疗肺动脉高压
  • 批准号:
    10257863
  • 财政年份:
    2021
  • 资助金额:
    $ 40万
  • 项目类别:
2-Hydroxybenzylamine for the prevention of Alzheimer's disease: Initial evaluation in humans
2-羟基苄胺预防阿尔茨海默病:对人类的初步评估
  • 批准号:
    9970647
  • 财政年份:
    2016
  • 资助金额:
    $ 40万
  • 项目类别:
2-Hydroxybenzylamine for the prevention of Alzheimer's disease: Initial evaluation in humans
2-羟基苄胺预防阿尔茨海默病:对人类的初步评估
  • 批准号:
    9564351
  • 财政年份:
    2016
  • 资助金额:
    $ 40万
  • 项目类别:
Gamma-ketoaldehyde scavengers for alcoholic liver disease
γ-酮醛清除剂治疗酒精性肝病
  • 批准号:
    8834691
  • 财政年份:
    2014
  • 资助金额:
    $ 40万
  • 项目类别:
Nutritional Intervention for Age-Related Muscular Function and Strength Losses
针对与年龄相关的肌肉功能和力量损失的营养干预
  • 批准号:
    7909359
  • 财政年份:
    2010
  • 资助金额:
    $ 40万
  • 项目类别:
Nutritional Intervention for Age-Related Muscular Function and Strength Losses
针对与年龄相关的肌肉功能和力量损失的营养干预
  • 批准号:
    9515437
  • 财政年份:
    2010
  • 资助金额:
    $ 40万
  • 项目类别:
Nutritional Intervention for Age-Related Muscular Function and Strength Losses
针对与年龄相关的肌肉功能和力量损失的营养干预
  • 批准号:
    8775460
  • 财政年份:
    2010
  • 资助金额:
    $ 40万
  • 项目类别:
Adjuvant Nutrition for Critically III Trauma Patients
危重 III 级创伤患者的辅助营养
  • 批准号:
    6582697
  • 财政年份:
    2003
  • 资助金额:
    $ 40万
  • 项目类别:
BODY PROTEIN METABOLISM & NUTRITION IN AIDS WASTING
身体蛋白质代谢
  • 批准号:
    6977108
  • 财政年份:
    2003
  • 资助金额:
    $ 40万
  • 项目类别:

相似国自然基金

Acrolein调控耳蜗核神经元-胶质细胞网络参与感音神经性耳聋发病机制的研究
  • 批准号:
    81570922
  • 批准年份:
    2015
  • 资助金额:
    65.0 万元
  • 项目类别:
    面上项目
acrolein在脊髓损伤后慢性疼痛发生发展中的作用及机制研究
  • 批准号:
    81171052
  • 批准年份:
    2011
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目

相似海外基金

In vivo anti cancer natural product synthesis based on reaction with endogenous acrolein
基于与内源性丙烯醛反应的体内抗癌天然产物合成
  • 批准号:
    23KJ0944
  • 财政年份:
    2023
  • 资助金额:
    $ 40万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Prodrug Strategy by Diels-Alder Reaction with Cancer-Derived Acrolein
通过与癌症衍生的丙烯醛进行第尔斯-阿尔德反应的前药策略
  • 批准号:
    23K17971
  • 财政年份:
    2023
  • 资助金额:
    $ 40万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Reactivity of acrolein produced by cancer cells: Application to selective cancer therapy
癌细胞产生的丙烯醛的反应性:在选择性癌症治疗中的应用
  • 批准号:
    21K05269
  • 财政年份:
    2021
  • 资助金额:
    $ 40万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Resarch on prevention of cyclophosphamide cardiotocity by removing acrolein
去除丙烯醛预防环磷酰胺强心死亡的研究
  • 批准号:
    20K08232
  • 财政年份:
    2020
  • 资助金额:
    $ 40万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
In vivo Click Reaction of Acrolein: Application to In vivo Synthetic Chemistry and Cancer Imaging
丙烯醛的体内点击反应:在体内合成化学和癌症成像中的应用
  • 批准号:
    18K14341
  • 财政年份:
    2018
  • 资助金额:
    $ 40万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Glial activation induced by unsaturated aldehyde acrolein in diabetic retinopathy
不饱和醛丙烯醛诱导糖尿病视网膜病变中的胶质细胞活化
  • 批准号:
    18K09393
  • 财政年份:
    2018
  • 资助金额:
    $ 40万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Mechanism of acrolein generation in diabetic retinopathy
糖尿病视网膜病变中丙烯醛的生成机制
  • 批准号:
    17K11442
  • 财政年份:
    2017
  • 资助金额:
    $ 40万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of fluorescent probes for acrolein, a product of lipid peroxidation
脂质过氧化产物丙烯醛荧光探针的开发
  • 批准号:
    17H06580
  • 财政年份:
    2017
  • 资助金额:
    $ 40万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Role of acrolein in the pathogenesis of diabetic retinopathy
丙烯醛在糖尿病视网膜病变发病机制中的作用
  • 批准号:
    26462657
  • 财政年份:
    2014
  • 资助金额:
    $ 40万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Novel Treatments of Acrolein-induced Cardiotoxicity
丙烯醛引起的心脏毒性的新疗法
  • 批准号:
    8610016
  • 财政年份:
    2013
  • 资助金额:
    $ 40万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了